OCT 28 2026
GSK — bepirovirsen $GSK
for chronic hepatitis B infection
Accepted APR 28 2026.
About
Hepatitis B is a viral infection that attacks the liver and can lead to lifelong illness if the virus persists. Bepirovirsen is an antisense oligonucleotide that binds to and silences HBV messenger RNA, preventing the virus from making proteins needed to replicate. By interrupting this viral production cycle, the drug may help control chronic HBV infection and reduce liver damage over time.
Pivotal trial
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on bepirovirsen
- Bepirovirsen leads to functional cure in one fifth of people with long-term hepatitis B - Aidsmap
- One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen - MSN
- Bepirovirsen Acts as a Functional Cure in Phase 3 Trials - The American Journal of Managed Care® (AJMC®)
- Bepirovirsen Breakthrough and Naldemedine Approval Could Be A Game Changer For Sino Biopharmaceutical (SEHK:1177) - simplywall.st
- Bepirovirsen Offers a Functional Cure for Hepatitis B - hepmag.com